Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type ...
In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type ...
The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimu...
Over the last few years, incretin‐based therapies have emerged as important agents in the treatment of type 2 diabetes ( T2D ). These agents exert their effect via the incretin ...